Drug · Other

Asparaginase

CI-DRUG-00000082Explore in graph →NCIt C286 CHEMBL2108989 CIViC Approved

Regulatory

Approvals (3)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

health-canada-dpdRegulatory2 approval records · authority, jurisdiction and indication text as published.

Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
CA Health Canada	—	Marketed in Canada as ERWINASE (DIN 02237815) under ATC L01XX02 ASPARAGINASE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Apr 9, 2021	Jul 1, 2009	health-canada-dpd
CA Health Canada	—	Marketed in Canada as KIDROLASE (DIN 01926438) under ATC L01XX02 ASPARAGINASE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Jul 7, 2021	Dec 31, 1974	health-canada-dpd

Health Canada records are DIN-level: one row per marketed product (brand, strength, form). The Drug Product Database does not publish indications, so no cancer is stated for these rows, and a cancelled or dormant DIN is the status of that one product — not a withdrawal of the molecule.

Data updated 17 hours agoSource updated unknown

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Active	Recruiting	Phase 3	Trials	Approvals	Jurisdictions	First approval	First trial
All cancers	Approved	Phase 4	11	4	43	111	3	CA, EU	Jan 14, 2016	1990-01
Leukemia	Approved	Phase 4	8	3	37	91	1	EU	Jan 14, 2016	1990-01
Non-Hodgkin Lymphoma	Phase4	Phase 4	1	0	2	12	0	—	—	1993-03
Malignant Nasopharyngeal Neoplasm	Phase3	Phase 3	1	0	1	2	0	—

Curated evidence

Clinical evidence (10)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–10 of 10 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
PRPS1 A190T1
Asparaginase + Cytarabine

Clinical trials

Trials with this intervention (112)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 51–100 of 112 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00098839	Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL)	completed	Phase 1 / Phase 2	134	Children's Oncology GroupNETWORK	4	Dec 12, 2017	clinicaltrials
NCT00693602	Compassionate Use of Erwinase For Pediatric Patients With Acute Lymphoblastic Leukemia Or Non Hodgkins Lymphoma	completed	Phase 1

Molecule

Record

Kind: Other
Mechanism: Asparagine hydrolytic enzyme
Aliases: ASP-1, Asparaginase, Asparaginase-E.Coli, Asparaginase II, Colaspase, E. coli asparaginase, E. coli l-asparaginase, Elspar, ERWINASE, Escherichia coli l-asparaginase, Kidrolase, KIDROLASE, L-Asnase, L-ASP, Laspar, L-asparaginase, L-Asparaginase, L-Asparagine Amidohydrolase, Lcf-ASP, Leucogen, Leunase, MK-965, NSC-109229, Paronal, Re-82-TAD-15, Serasa, Spectrila

Data updated 20 hours agoSource updated unknown

Identifiers

Codes (6)

Upstream identifiers kept as first-class codes; each links to its registry where a stable public URL exists.

System	Code	Label
ATC (WHO)	L01XX02	ASPARAGINASE
DIN (Health Canada)	01926438	KIDROLASE
DIN (Health Canada)	02237815

PRPS1 D183E1
Asparaginase + Cytarabine + Daunorubicin + MethotrexateSubstitutes	B Lymphoblastic Leukemia/LymphomaCURATED_BROADER	Predictive	D	Does Not Support Resistance	3	accepted	EID7927 Lentiviral-mediated overexpression of PRPS1 D183E in Reh cells resulted no difference in response to Methotrexate, Cytarabine, Daunorubicin, or L-Asparginase compared to empty vector and wildtype PRPS… (full text at CIViC) PMID 25962120 · Li et al., 2015 · Open in CIViC	civic

PRPS1 D183E1

Asparaginase + Cytarabine + Daunorubicin + MethotrexateSubstitutes

B Lymphoblastic Leukemia/LymphomaCURATED_BROADER

Predictive

Does Not Support Resistance

accepted

EID7927

Lentiviral-mediated overexpression of PRPS1 D183E in Reh cells resulted no difference in response to Methotrexate, Cytarabine, Daunorubicin, or L-Asparginase compared to empty vector and wildtype PRPS… (full text at CIViC)

PMID 25962120 · Li et al., 2015 · Open in CIViC

civic

PRPS1 K176N1
Asparaginase + Cytarabine + Daunorubicin + MethotrexateSubstitutes	B Lymphoblastic Leukemia/LymphomaCURATED_BROADER	Predictive	D	Does Not Support Resistance	3	accepted	EID7926 Lentiviral-mediated overexpression of PRPS1 K176N in Reh cells resulted no difference in response to Methotrexate, Cytarabine, Daunorubicin, or L-Asparginase compared to empty vector and wildtype PRPS… (full text at CIViC) PMID 25962120 · Li et al., 2015 · Open in CIViC	civic

PRPS1 K176N1

Asparaginase + Cytarabine + Daunorubicin + MethotrexateSubstitutes

B Lymphoblastic Leukemia/LymphomaCURATED_BROADER

Predictive

Does Not Support Resistance

accepted

EID7926

Lentiviral-mediated overexpression of PRPS1 K176N in Reh cells resulted no difference in response to Methotrexate, Cytarabine, Daunorubicin, or L-Asparginase compared to empty vector and wildtype PRPS… (full text at CIViC)

PMID 25962120 · Li et al., 2015 · Open in CIViC

civic

PRPS1 L191F1
Asparaginase + Daunorubicin + MethotrexateSubstitutes	B Lymphoblastic Leukemia/LymphomaCURATED_BROADER	Predictive	D	Does Not Support Resistance	3	accepted	EID7923 Lentiviral-mediated overexpression of PRPS1 L191F in Reh cells resulted no difference in response to Methotrexate, Daunorubicin, or L-Asparginase compared to empty vector and wildtype PRPS1 overexpres… (full text at CIViC) PMID 25962120 · Li et al., 2015 · Open in CIViC	civic

PRPS1 L191F1

Asparaginase + Daunorubicin + MethotrexateSubstitutes

B Lymphoblastic Leukemia/LymphomaCURATED_BROADER

Predictive

Does Not Support Resistance

accepted

EID7923

Lentiviral-mediated overexpression of PRPS1 L191F in Reh cells resulted no difference in response to Methotrexate, Daunorubicin, or L-Asparginase compared to empty vector and wildtype PRPS1 overexpres… (full text at CIViC)

PMID 25962120 · Li et al., 2015 · Open in CIViC

civic

PRPS1 N144S1
Asparaginase + Daunorubicin + MethotrexateSubstitutes	B Lymphoblastic Leukemia/LymphomaCURATED_BROADER	Predictive	D	Does Not Support Resistance	3	accepted	EID7930 Lentiviral-mediated overexpression of PRPS1 N144S in Reh cells resulted no difference in response to Methotrexate, Daunorubicin, or L-Asparginase compared to empty vector and wildtype PRPS1 overexpres… (full text at CIViC) PMID 25962120 · Li et al., 2015 · Open in CIViC	civic

PRPS1 N144S1

Asparaginase + Daunorubicin + MethotrexateSubstitutes

B Lymphoblastic Leukemia/LymphomaCURATED_BROADER

Predictive

Does Not Support Resistance

accepted

EID7930

Lentiviral-mediated overexpression of PRPS1 N144S in Reh cells resulted no difference in response to Methotrexate, Daunorubicin, or L-Asparginase compared to empty vector and wildtype PRPS1 overexpres… (full text at CIViC)

PMID 25962120 · Li et al., 2015 · Open in CIViC

civic

PRPS1 S103N1
Asparaginase + Cytarabine + Daunorubicin + MethotrexateSubstitutes	B Lymphoblastic Leukemia/LymphomaCURATED_BROADER	Predictive	D	Does Not Support Resistance	3	accepted	EID7925 Lentiviral-mediated overexpression of PRPS1 S103N in Reh cells resulted no difference in response to Methotrexate, Cytarabine, Daunorubicin, or L-Asparginase compared to empty vector and wildtype PRPS… (full text at CIViC) PMID 25962120 · Li et al., 2015 · Open in CIViC	civic

PRPS1 S103N1

Asparaginase + Cytarabine + Daunorubicin + MethotrexateSubstitutes

B Lymphoblastic Leukemia/LymphomaCURATED_BROADER

Predictive

Does Not Support Resistance

accepted

EID7925

Lentiviral-mediated overexpression of PRPS1 S103N in Reh cells resulted no difference in response to Methotrexate, Cytarabine, Daunorubicin, or L-Asparginase compared to empty vector and wildtype PRPS… (full text at CIViC)

PMID 25962120 · Li et al., 2015 · Open in CIViC

civic

PRPS1 S103T1
Asparaginase + Cytarabine + Daunorubicin + MethotrexateSubstitutes	B Lymphoblastic Leukemia/LymphomaCURATED_BROADER	Predictive	D	Does Not Support Resistance	3	accepted	EID7924 Lentiviral-mediated overexpression of PRPS1 S103T in Reh cells resulted no difference in response to Methotrexate, Cytarabine, Daunorubicin, or L-Asparginase compared to empty vector and wildtype PRPS… (full text at CIViC) PMID 25962120 · Li et al., 2015 · Open in CIViC	civic

PRPS1 S103T1

Asparaginase + Cytarabine + Daunorubicin + MethotrexateSubstitutes

B Lymphoblastic Leukemia/LymphomaCURATED_BROADER

Predictive

Does Not Support Resistance

accepted

EID7924

Lentiviral-mediated overexpression of PRPS1 S103T in Reh cells resulted no difference in response to Methotrexate, Cytarabine, Daunorubicin, or L-Asparginase compared to empty vector and wildtype PRPS… (full text at CIViC)

PMID 25962120 · Li et al., 2015 · Open in CIViC

civic

PRPS1 T303S1
Asparaginase + Cytarabine + Daunorubicin + MethotrexateSubstitutes	B Lymphoblastic Leukemia/LymphomaCURATED_BROADER	Predictive	D	Does Not Support Resistance	3	accepted	EID7929 Lentiviral-mediated overexpression of PRPS1 T303S in Reh cells resulted no difference in response to Methotrexate, Cytarabine, Daunorubicin, or L-Asparginase compared to empty vector and wildtype PRPS… (full text at CIViC) PMID 25962120 · Li et al., 2015 · Open in CIViC	civic

PRPS1 T303S1

Asparaginase + Cytarabine + Daunorubicin + MethotrexateSubstitutes

B Lymphoblastic Leukemia/LymphomaCURATED_BROADER

Predictive

Does Not Support Resistance

accepted

EID7929

Lentiviral-mediated overexpression of PRPS1 T303S in Reh cells resulted no difference in response to Methotrexate, Cytarabine, Daunorubicin, or L-Asparginase compared to empty vector and wildtype PRPS… (full text at CIViC)

PMID 25962120 · Li et al., 2015 · Open in CIViC

civic

ASNS Amplification1
Asparaginase	Malignant Ovarian Neoplasm	Predictive	D	Supports Resistance	2	accepted	EID953 ASNS amplification and expression was associated with resistance to L-asparaginase in ovarian cancer and leukemia cell lines. ASNS silencing increased sensitivity to l-ASP in 2/3 of ovarian cancer cel… (full text at CIViC) PMID 17088436 · Lorenzi et al., 2006 · Open in CIViC	civic

ASNS Amplification1

Asparaginase

Malignant Ovarian Neoplasm

Predictive

Supports Resistance

accepted

EID953

ASNS amplification and expression was associated with resistance to L-asparaginase in ovarian cancer and leukemia cell lines. ASNS silencing increased sensitivity to l-ASP in 2/3 of ovarian cancer cel… (full text at CIViC)

PMID 17088436 · Lorenzi et al., 2006 · Open in CIViC

civic

ASNS Fusion1
Asparaginase	T Lymphoblastic Leukemia/LymphomaCURATED_BROADER	Predictive	D	Supports Resistance	3	submitted	EID5926 Fusion of the KMT2E promoter with the complete coding sequence of ASNS was observed in two relapsed ETP-ALL patients treated with l-asparaginase. The variant was shown to significantly increase ASNS e… (full text at CIViC) PMID 28069604 · Khater et al., 2017 · Open in CIViC	civic

ASNS Fusion1

Asparaginase

T Lymphoblastic Leukemia/LymphomaCURATED_BROADER

Predictive

Supports Resistance

submitted

EID5926

Fusion of the KMT2E promoter with the complete coding sequence of ASNS was observed in two relapsed ETP-ALL patients treated with l-asparaginase. The variant was shown to significantly increase ASNS e… (full text at CIViC)

PMID 28069604 · Khater et al., 2017 · Open in CIViC

civic